Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.4
5.2
Journals
Cancers
Special Issues
The Biology of CD44 and Its Role in Cancer Progression:...
share announcement

The Biology of CD44 and Its Role in Cancer Progression: Therapeutic Implications

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Molecular Cancer Biology".

Deadline for manuscript submissions: 30 June 2024 | Viewed by 1425

Special Issue Editor

Prof. Dr. Paraskevi Heldin

E-Mail Website
Guest Editor
Department of Medical Biochemistry and Microbiology, Uppsala University, 75 123 Uppsala, Sweden
Interests: hyaluronan; cell signaling; inflammation; growth factor; extracellular matrix; tumor microenvironment

Special Issue Information

Dear Colleagues,

CD44 is a signalling hub that integrates and transduces microenvironmental cues to the cytoplasm and nucleus, and thus regulates physiological processes. The overexpression and/or over activity of CD44 is linked to diseases such as cancer, immune dysregulation and fibrosis. Alternative splicing of the CD44 transcript results in the formation of the standard CD44 (CD44s) and variant CD44 (CD44v) isoforms, which all contain the extracellular hyaluronan-binding region, and the conserved transmembrane and cytoplasmic regions. CD44 is a cancer stem cell (CSC) marker; therefore, it regulates tumour initiation and chemoresistance, promotes PD-L1 expression, thus eliciting immunosuppression in cancers, and suppresses p53-induced cellular death.

The purpose of this Special Issue is to shed light on the molecular mechanisms that underlie CD44 signalling, its role in cancer progression and in the microenvironment of cancer cells. A more thorough understanding of the biological role of CD44 may facilitate the development of anti-cancer therapies. This Special Issue welcomes reviews, as well as original research articles, by 31 January 2024.

Prof. Dr. Paraskevi Heldin
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • CD44
  • hyaluronan
  • receptor tyrosine kinase
  • cytokine receptors
  • tumour microenvironment
  • stemness
  • metastases
  • prognostic factor
  • vascular leakage
  • tumour-derived exosomes

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

18 pages, 1127 KiB  
Review
CD44: A New Prognostic Marker in Colorectal Cancer?
by Pina Ziranu, Andrea Pretta, Valentina Aimola, Flaviana Cau, Stefano Mariani, Alessandra Pia D’Agata, Claudia Codipietro, Daiana Rizzo, Veronica Dell’Utri, Giorgia Sanna, Giusy Moledda, Andrea Cadoni, Eleonora Lai, Marco Puzzoni, Valeria Pusceddu, Massimo Castagnola, Mario Scartozzi and Gavino Faa
Cancers 2024, 16(8), 1569; https://doi.org/10.3390/cancers16081569 - 19 Apr 2024
Viewed by 304
Abstract
Cluster of differentiation 44 (CD44) is a non-kinase cell surface glycoprotein. It is overexpressed in several cell types, including cancer stem cells (CSCs). Cells overexpressing CD44 exhibit several CSC traits, such as self-renewal, epithelial–mesenchymal transition (EMT) capability, and resistance to chemo- and radiotherapy. [...] Read more.
Cluster of differentiation 44 (CD44) is a non-kinase cell surface glycoprotein. It is overexpressed in several cell types, including cancer stem cells (CSCs). Cells overexpressing CD44 exhibit several CSC traits, such as self-renewal, epithelial–mesenchymal transition (EMT) capability, and resistance to chemo- and radiotherapy. The role of CD44 in maintaining stemness and the CSC function in tumor progression is accomplished by binding to its main ligand, hyaluronan (HA). The HA-CD44 complex activates several signaling pathways that lead to cell proliferation, adhesion, migration, and invasion. The CD44 gene regularly undergoes alternative splicing, resulting in the standard (CD44s) and variant (CD44v) isoforms. The different functional roles of CD44s and specific CD44v isoforms still need to be fully understood. The clinicopathological impact of CD44 and its isoforms in promoting tumorigenesis suggests that CD44 could be a molecular target for cancer therapy. Furthermore, the recent association observed between CD44 and KRAS-dependent carcinomas and the potential correlations between CD44 and tumor mutational burden (TMB) and microsatellite instability (MSI) open new research scenarios for developing new strategies in cancer treatment. This review summarises current research regarding the different CD44 isoform structures, their roles, and functions in supporting tumorigenesis and discusses its therapeutic implications. Full article
(This article belongs to the Special Issue The Biology of CD44 and Its Role in Cancer Progression: Therapeutic Implications)
►▼ Show Figures

Figure 1

12 pages, 266 KiB  
Review
CD44 in Bladder Cancer
by Jason Duex and Dan Theodorescu
Cancers 2024, 16(6), 1195; https://doi.org/10.3390/cancers16061195 - 18 Mar 2024
Viewed by 717
Abstract
The glycoprotein CD44, with its many isoforms and variations in carbohydrate patterning, participates in a diverse set of cellular functions. This fact leads to the protein playing a role in many normal and pathologic cellular processes including a role in cancer progression and [...] Read more.
The glycoprotein CD44, with its many isoforms and variations in carbohydrate patterning, participates in a diverse set of cellular functions. This fact leads to the protein playing a role in many normal and pathologic cellular processes including a role in cancer progression and metastasis. These same facts make CD44 a strong therapeutic target in many cancer types, including bladder cancer. Full article
(This article belongs to the Special Issue The Biology of CD44 and Its Role in Cancer Progression: Therapeutic Implications)
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop